Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors

…, N Jenner, M Béhé, C Angerstein - The Journal of Nuclear …, 1999 - search.proquest.com
The high sensitivity of pentagastrin stimulation in detecting primary or metastatic medullary
thyroid cancer (MTC) suggests widespread expression of the corresponding receptor type on …

Therapeutic advantages of Auger electron-over β-emitting radiometals or radioiodine when conjugated to internalizing antibodies

…, M Béhé, M Löhr, G Sgouros, C Angerstein… - European journal of …, 2000 - Springer
Recent studies suggest a higher anti-tumour efficacy of internalizing monoclonal antibodies
(MAbs) when labelled with Auger electron emitters, as compared with β-emitters. The aim of …

Improved kinetic stability of DTPA-dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation …

M Béhé, W Becker, M Gotthardt, C Angerstein… - European journal of …, 2003 - Springer
The development of monofunctional DTPA derivatives has been a major breakthrough in the
labelling of proteins or peptides with a variety of radiometals. Although this methodology is …

Retracted: Radioimmunotherapy of small‐volume disease of metastatic colorectal cancer: Results of a phase II trial with the iodine‐131–labeled humanized anti …

…, PM Markus, S Gratz, C Angerstein… - … Journal of the …, 2002 - Wiley Online Library
BACKGROUND Whereas radioimmunotherapy (RIT) has shown disappointing results in
bulky, solid tumors, preclinical results in small‐volume disease and in an adjuvant setting are …

Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential

TM Behr, M Béhé, C Angerstein, S Gratz, R Mach… - Clinical cancer …, 1999 - AACR
The high sensitivity of pentagastrin stimulation in detecting primary or metastatic medullary
thyroid cancer (MTC) suggests widespread expression of the corresponding receptor type on …

Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial …

TM Behr, AL Salib, T Liersch, M Béhé, C Angerstein… - Clinical cancer …, 1999 - AACR
At the time of surgery, occult metastases (micrometastases) are present in more than 50% of
colorectal cancer patients, and the liver is the most frequent site of apparent metastatic …

Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with β …

…, G Sgouros, MG Stabin, M Béhé, C Angerstein… - Clinical cancer …, 1999 - AACR
Usually, the red marrow (RM) is the first dose-limiting organ in radioimmunotherapy. However,
several studies have obtained only poor correlations between the marrow doses and the …

Biodistribution, blood half-life, and receptor binding of a somatostatin-dextran conjugate

M Behe, J Du, W Becker, T Behr, C Angerstein… - Medical Oncology, 2001 - Springer
Derivatives of somatostatin (sms) are attracting increasing interest as part of the treatment of
several cancer diseases expressing sms receptors (srs). Radiolabeled sms analogs can …

[PDF][PDF] Cholecystokinin-B/Gastrin Receptor Binding Peptides: Preclinical Development and Evaluation of Their Diagnostic and Therapeutic Potential I

C Angerstein, S Gratz, R Mach, L Hagemann, N Jenner… - academia.edu
The high sensitivity of pentagastrin stimulation in detecting primary or metastatic medullary
thyroid cancer (MTC) suggests widespread expression of the corresponding receptor type on …

Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys

M Béhé, G Kluge, W Becker, M Gotthardt… - Journal of Nuclear …, 2005 - Soc Nuclear Med
… We thank Birgit Herbst, Ulla Cramer, and Christa Angerstein for technical assistance. We
are grateful to the participants of the COST action B12 for fruitful discussions. This work was …